secwatch.observer — SEC 8-K summary ====================================== Issuer: Scribe Therapeutics, Inc. (SCTX) CIK: 0001853921 Form: 8-K Filed at: 2026-11-12T21:20:14+00:00 Accession: 0001193125-26-458486 Event type: earnings Sentiment: neutral Materiality: 0.45 Item codes: 2.02, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 Scribe Therapeutics Q3 2026 net loss $9.9M ($0.68/sh); $174.2M cash funds operations into 1H 2029 -------------------------------------------------------------------------------- - Net loss $9.9M ($0.68 per basic and diluted share) vs $6.5M net loss in Q2 2026; R&D $8.3M, G&A $4.2M, collaboration revenue $1.6M. - Cash, equivalents and marketable securities $174.2M at Sept 30, 2026 vs $43.0M at June 30, after ~$140.2M net IPO/private placement proceeds; runway into 1H 2029. - STX-1150 Phase 1 in elevated LDL-C ongoing; safety, tolerability and LDL-C data from single ascending dose expected 1H 2027; NHP data showed >50% LDL-C cut at 0.75 mg/kg for two years. - Expanded Sanofi collaboration to include ELXR epigenetic silencing technology, adding to XE gene editing and extending Sanofi's target nomination period; no financial terms disclosed. - July 2026 IPO upsized and priced at high end; ~$155.5M gross proceeds including underwriters' option and concurrent Sanofi private placement at the IPO price. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1853921/000119312526458486/0001193125-26-458486-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1853921/000119312526458486/sctx-20261112.htm HTML page: https://secwatch.observer/filing/0001193125-26-458486 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer